Gastrointestinal Cancer Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results…
View More
William Harris, MD, discusses a feasibility study on using biospecimen-based multi-platform profiling for patients with resected biliary tract cancer.
View More
Adam Diehl, MD, discusses an ongoing study assessing the ability to obtain NGS, ctDNA monitoring, and organoid drug sensitivity screening in patients with resected localized biliary tract cancer.
View More
Gentry King, MD, discusses an ongoing feasibility study on multiomic platform‑based testing in patients with localized and resectable biliary tract cancers.
View More
Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and discusses new advancements in the treatment of HER2+ gastric cancer.
View More
Dr Pedersen discusses the history of small bowel adenocarcinoma, and phase 2 research informing the evolving treatment landscape for this disease.
View More
Dr Pedersen talks about how short-course neoadjuvant chemotherapy improved outcomes over standard treatment in patients with locally advanced rectal cancer in the phase 3 RAPIDO trial.
View More
Eileen M O'Reilly, MD, highlights the treatment landscape of biliary cancer and new developments in 2020.
View More
Dr Chiorean shares takeaways of the SWOG 1505 trial which did not determine perioperative modified FOLFIRINOX was superior to gemcitabine plus nab-paclitaxel in resectable pancreatic cancer.
View More
Stay in the know.
OncNet Newsletter